Beneficial effects of FK506 for experimental temporal lobe epilepsy.
FK506, originally classified as an immunosuppressant, may also be implicated in some events in the central nervous system. FK506 elicits both neuroprotective and neurotrophic effects in vitro. FK506 is neuroprotective for focal cerebral ischemia, but it is not clear whether FK506 has neuroprotective effects for other brain diseases. In this study, we investigated possible neuroprotective effects of FK506 in experimental temporal lobe epilepsy (TLE) induced by kainic acid (KA) or trimethyltin (TMT). In rat models, we observed marked protection against seizures, abnormal behaviors, and accompanying delayed neuronal damage in the hippocampus by the systemic injection of FK506.
Nishimura
Tsutomu
T
Department of Pediatrics, Tokyo Women's Medical University, Tokyo, Japan.
Imai
Hideki
H
Minabe
Yoshio
Y
Sawa
Akira
A
Kato
Nobumasa
N
D000374:Aggression / Q000187:drug effects; D000818:Animals; D000927:Anticonvulsants; D002470:Cell Survival / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004833:Epilepsy, Temporal Lobe / Q000139:chemically induced / Q000188:drug therapy* / Q000523:psychology; D018690:Excitatory Amino Acid Agonists; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D020287:In Situ Nick-End Labeling; D007608:Kainic Acid; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D012640:Seizures / Q000139:chemically induced / Q000503:physiopathology; D016559:Tacrolimus / Q000627:therapeutic use*; D014298:Trimethyltin Compounds
D000927:Anticonvulsants; D018690:Excitatory Amino Acid Agonists; D007166:Immunosuppressive Agents; D014298:Trimethyltin Compounds; C046488:trimethyltin; D007608:Kainic Acid; D016559:Tacrolimus